Kapitalo Investimentos Ltda Sells 350,000 Shares of Kenvue Inc. $KVUE

Kapitalo Investimentos Ltda cut its stake in Kenvue Inc. (NYSE:KVUE) by 14.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,000,000 shares of the company’s stock after selling 350,000 shares during the period. Kenvue accounts for 6.6% of Kapitalo Investimentos Ltda’s holdings, making the stock its 6th biggest holding. Kapitalo Investimentos Ltda’s holdings in Kenvue were worth $34,500,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in KVUE. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Kenvue by 27.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 310,686 shares of the company’s stock valued at $5,042,000 after purchasing an additional 66,192 shares during the period. Renaissance Capital LLC increased its holdings in shares of Kenvue by 55.8% during the third quarter. Renaissance Capital LLC now owns 980,436 shares of the company’s stock valued at $15,912,000 after purchasing an additional 351,259 shares during the period. Allstate Corp acquired a new position in shares of Kenvue during the third quarter valued at $1,152,000. Aberdeen Group plc increased its holdings in shares of Kenvue by 84.1% during the third quarter. Aberdeen Group plc now owns 1,411,380 shares of the company’s stock valued at $22,914,000 after purchasing an additional 644,930 shares during the period. Finally, Oak Thistle LLC bought a new position in shares of Kenvue in the fourth quarter valued at approximately $1,563,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

NYSE:KVUE opened at $17.31 on Wednesday. The business’s 50-day moving average price is $17.89 and its 200 day moving average price is $17.13. The firm has a market cap of $33.22 billion, a P/E ratio of 22.47, a PEG ratio of 3.99 and a beta of 0.61. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same period in the previous year, the company earned $0.26 earnings per share. Kenvue’s revenue was up 3.2% compared to the same quarter last year. As a group, sell-side analysts predict that Kenvue Inc. will post 1.1 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were given a $0.2075 dividend. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Wall Street Analyst Weigh In

KVUE has been the subject of several recent analyst reports. Barclays decreased their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Canaccord Genuity Group upped their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Citigroup cut their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. UBS Group cut their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a report on Wednesday, April 8th. Three equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.